1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow VRD: new trials by email Literature Review of VRD trials Research Report on VRD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma anti-BCMA CAR-T, VRd - Multiple Myeloma | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2023-04-04 | 2025-08-03 |
| Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients Chidamide+VRD, VRD - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 50 | 2019-07-15 | 2019-07-19 |
Multiple Myeloma (3)
Institute of Hematology & Blood Diseases Hospital, China (1) · The Affiliated People's Hospital of Ningbo University (1) · The First Affiliated Hospital of Soochow University (1)
China (2)